170632-32-3Relevant academic research and scientific papers
Preferential inhibition of release of pro-inflammatory cytokines
-
Page/Page column 7, (2008/06/13)
A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of
Method of treating disorders related to protease-activated receptors-induced cell activation
-
, (2008/06/13)
A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.
1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)-indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis
Lien, Jin-Cherng,Lee, Fang-Yu,Huang, Li-Jiau,Pan, Shiow-Lin,Guh, Jih-Hwa,Teng, Che-Ming,Kuo, Sheng-Chu
, p. 4947 - 4949 (2007/10/03)
Antiapoptotic agents based on 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (22, YC-1) derivatives were explored for effective treatment of sepsis and septic shock. We found that compound 22, 1-benzyl-3-(5′-methoxymethyl-2′-furyl)indazole (27), and 1-phe
Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole analogues as novel antiplatelet agents
Le,Lien,Huang,Huang,Tsai,Teng,Wu,Cheng,Kuo
, p. 3746 - 3749 (2007/10/03)
1-Benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, co
